Relationship between clinical manifestations and serological profile in patients affected by Systemic Lupus Erythematosus

被引:2
作者
Nicola, Stefania [1 ]
Borrelli, Richard [1 ]
Corradi, Federica [1 ]
Lo Sardo, Luca [1 ]
Badiu, Iuliana [1 ]
Romito, Alessandra [2 ]
Rashidy, Nicolo [1 ]
Quinternetto, Anna [1 ]
Mazzola, Marina [1 ]
Meli, Federico [1 ]
Saracco, Elena [1 ]
Vitali, Ilaria [1 ]
Cosseddu, Domenico [2 ]
Brussino, Luisa [1 ]
机构
[1] Univ Turin, Mauriziano Hosp, Dept Med Sci, Allergy & Clin Immunol Unit, Turin, Italy
[2] Mauriziano Hosp, Dept Lab Med, Turin, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
lupus; SLE; autoantibodies; serological profile; immunology; ANTI-DSDNA ANTIBODIES; PATHOGENESIS; ASSOCIATION;
D O I
10.3389/fimmu.2024.1390642
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by a variety of both signs and symptoms; it mainly affects women of childbearing age, with an estimated prevalence of 24/100,000 people in Europe and North America. SLE is often described as an antibodies-driven disease as its clinical manifestations are usually associated with the presence or the absence of specific antibodies.Objectives To evaluate clinical manifestations in patients with SLE and to assess the relationship with the presence of specific antibodies by using real-world data.Methods A retrospective study was performed; the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus were used to classify patients with SLE. Data concerning serological profiles (which included Antinuclear antibodies - ANA, anti dsDNA, anti-Ro/SS-A, anti-La/SS-B, anti-Smith) were gathered along with medical records of clinical manifestations. Complement levels were also tested for possible clinical correlations. chi(2) or Fisher's exact tests were utilized to establish associations between autoantibodies and symptoms. The odds ratios (OR) and their 95% confidence intervals (CI) were computed. No correction was made for multiple testing; only a p-value 0.01 <= was considered significant.Results One-hundred and twenty-seven patients (n=127, mean age 53.43 +/- 14.02) were enrolled in this study. Anti-dsDNA antibodies were found to be statistically significant for both malar rash and proteinuria; anti-Ro/SSA antibodies showed an association with photosensitivity and pericarditis; furthermore, a strong association was found between anti-Ro antibodies and proteinuria, but only if anti-dsDNA antibodies were present as well. Patients who tested positive for anti-La/SSB antibodies correlated with a threefold increase in the risk of developing pericarditis. Lastly, anti-Smith appeared to be associated with NPSLE as well as an increased risk for both autoimmune hemolytic anemia and thrombocytopenia.Conclusions In our study, many associations confirmed those found in previous studies; however, new relationships between antibodies and clinical manifestations were found thus indicating the need for additional evaluations to assess these correlations further.
引用
收藏
页数:7
相关论文
共 41 条
  • [1] Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus
    Ahn, Sung Soo
    Jung, Seung Min
    Yoo, Juyoung
    Lee, Sang-Won
    Song, Jason Jungsik
    Park, Yong-Beom
    [J]. RHEUMATOLOGY INTERNATIONAL, 2019, 39 (11) : 1937 - 1944
  • [2] Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI [10.1002/art.40930, 10.1136/annrheumdis-2018-214819]
  • [3] Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort
    Arroyo-Avila, Mariangeli
    Santiago-Casas, Yesenia
    McGwin, Gerald, Jr.
    Cantor, Ryan S.
    Petri, Michelle
    Ramsey-Goldman, Rosalind
    Reveille, John D.
    Kimberly, Robert P.
    Alarcon, Graciela S.
    Vila, Luis M.
    Brown, Elizabeth E.
    [J]. CLINICAL RHEUMATOLOGY, 2015, 34 (07) : 1217 - 1223
  • [4] Asif S, 2022, REUMATOL CLIN, V18, P464, DOI [10.1016/j.reuma.2021.06.002, 10.1016/j.reumae.2021.06.005]
  • [5] Complement as a Biomarker for Systemic Lupus Erythematosus
    Ayano, Masahiro
    Horiuchi, Takahiko
    [J]. BIOMOLECULES, 2023, 13 (02)
  • [6] Complement in Lupus Nephritis: New Perspectives
    Bao, Lihua
    Cunningham, Patrick N.
    Quigg, Richard J.
    [J]. KIDNEY DISEASES, 2015, 1 (02) : 91 - 99
  • [7] The global burden of SLE: prevalence, health disparities and socioeconomic impact
    Carter, Erin E.
    Barr, Susan G.
    Clarke, Ann E.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (10) : 605 - 620
  • [8] The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus
    Catalina, Michelle D.
    Owen, Katherine A.
    Labonte, Adam C.
    Grammer, Amrie C.
    Lipsky, Peter E.
    [J]. JOURNAL OF AUTOIMMUNITY, 2020, 110
  • [9] Ant -Sm Antibody, Damage Index, and Corticosteroid Use Are Associated with Cardiac Involvement in Systemic Lupus Erythematosus: Data from a Prospective Registry Study
    Choe, Jung-Yoon
    Lee, Shin-Seok
    Kwak, Sang Gyu
    Kim, Seong-Kyu
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (21)
  • [10] Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study
    Chung, Min Kyung
    Park, Jin Su
    Lim, Hyunsun
    Lee, Chan Hee
    Lee, Jisoo
    [J]. LUPUS, 2021, 30 (04) : 674 - 679